MAP Kinase Inhibitors in Cancer and Other Diseases

1. Introduction

Protein kinases constitute a substantial enzyme family responsible for catalyzing protein phosphorylation events. Within the human genome, 518 genes encoding these proteins have been identified; of these, 478 are categorized as members of the conventional protein kinase group, while the remaining 40 are designated as atypical kinases [1]. The process of phosphorylation stands as a cornerstone regulatory mechanism governing a vast array of cellular functions, encompassing proliferation, cell cycle progression, programmed cell death, motility, growth, and differentiation. Disruption of normal kinase activity can precipitate profound alterations in these physiological processes. Indeed, aberrant kinase regulation is frequently implicated in the pathogenesis of various malignancies, viral infections, neurodegenerative conditions, ischemic injury, and certain proliferative diseases [1].

The mitogen-activated protein kinase (MAPK) family represents a particularly well-studied group. Members of this family orchestrate diverse biological outcomes through the targeted phosphorylation of specific substrates—including transcription factors and other kinases—located within the cell membrane, cytoplasm, and nucleus. Consequently, they exert control over a wide spectrum of cellular activities, such as proliferation, differentiation, apoptosis, and immune responses. The inaugural MAPK signaling cascade to be elucidated was the RAS-RAF-ERK pathway, defined by its terminal effectors, ERK1 and ERK2. This axis plays a pivotal role in governing cell proliferation, differentiation, and survival, with its dysregulation representing a frequent hallmark of cancer. In numerous instances, aberrant ERK activity in tumors is driven by mutations within the upstream components RAS and RAF. Another subfamily, the c-Jun N-terminal kinases (JNKs), were initially characterized by their capacity to bind and phosphorylate the transcription factor AP-1 (JUN) at serine residues 63 and 73 within its transactivation domain. This group comprises three alternatively spliced gene products: JNK1, JNK2, and JNK3. Pathological hyperactivation of JNK signaling is observed across a range of cancers, as well as in inflammatory and neurodegenerative disorders. The p38 kinase subfamily constitutes yet another distinct MAPK branch, encompassing four isoforms designated alpha, beta, gamma, and delta. Stimuli such as pathogens or inflammatory cytokines initiate signaling cascades mediated by p38 kinases; consequently, abnormal p38 activity is documented in both inflammatory conditions and neoplastic diseases. A critical downstream substrate and signal transducer within this context is serum/glucocorticoid-regulated kinase 1 (SGK1), which also plays a significant role in malignant progression. The fourth major MAPK module is the MEK5-ERK5 cascade, whose activation is a common occurrence in tumorigenesis and is associated with anti-apoptotic signaling and the development of chemoresistance [2] (Figure 1).

The therapeutic potential of small-molecule kinase inhibitors has garnered considerable attention in drug discovery and clinical application. A substantial repertoire of these agents exists, exhibiting varying degrees of target specificity; several have already received approval for oncological indications, while numerous others are under investigation in diverse phases of clinical trials. Inhibitors targeting MAPK pathways are no exception, with a plethora of compounds employed for both preclinical research and therapeutic use. Many MAPK inhibitors are currently being evaluated across multiple clinical phases for cancer and other disease states. Beyond the MAPK family, other prominent kinase targets for pharmacological intervention include tyrosine kinases, cyclin-dependent kinases (CDKs), and aurora kinases [3].

2. MAP Kinase Inhibitors

2.1. ERK Inhibitors

The ERK1 and ERK2 isoforms exhibit approximately 84% sequence homology and are typically discussed interchangeably due to their overlapping functions and shared upstream activation mechanisms. ERK5, though less prominently featured in the literature, maintains structural resemblance to its ERK1/2 counterparts and shares numerous downstream substrates, including c-Myc and c-Fos, thus contributing to the regulation of analogous biological processes [2,3]. Interestingly, when cells are exposed to pharmacological ERK1/2 blockade or when these genes are genetically ablated, a compensatory surge in ERK5 phosphorylation and activity has been observed, which sustains proliferative signaling across various tumor types, including melanoma, colorectal carcinoma, and triple-negative breast cancer [4]. This adaptive response has been recognized as a major obstacle limiting the therapeutic efficacy of ERK1/2-directed monotherapies in the clinic [5].

2.1.1. Ulixertinib (BVD-523 / VRT752271)

Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2 [6] (Figure 2, Table 1).

A first-in-human dose-finding study (NCT01781429) enrolling 135 individuals with advanced malignancies established the phase II recommended dosing regimen at 600 mg administered twice daily [6]. The safety profile was dominated by gastrointestinal and dermatological manifestations, with diarrhea, fatigue, nausea, and acneiform rash occurring in 48%, 42%, 41%, and 31% of participants, respectively. Encouragingly, objective tumor shrinkage was documented in 17% of cases treated at or beyond the maximum tolerated exposure level, with responses spanning tumors driven by BRAF and NRAS mutations, including those that had previously progressed on BRAF or MEK-targeted therapies [6].

Extensive preclinical characterization has shown that ulixertinib exerts potent and highly selective inhibition of ERK1/2, leading to diminished proliferative capacity and enhanced apoptotic execution as measured by caspase activation across susceptible cell lines [7]. In murine xenograft systems, the compound elicited dose-responsive tumor stasis and regression, even in models engineered to resist BRAF and MEK inhibition. When paired with BRAF-directed agents in BRAFV600E-mutant melanoma models, ulixertinib produced synergistic growth suppression, reinforcing its potential utility in circumventing resistance to conventional MAPK pathway blockade [7].

The combination of ulixertinib with standard-of-care gemcitabine and nab-paclitaxel was explored in a phase Ib trial for treatment-naïve metastatic pancreatic ductal adenocarcinoma [8]. Tolerability challenges at the 600 mg dose necessitated de-escalation to 450 mg twice daily as the recommended phase II dose. Among the 15 patients receiving the three-drug regimen, progression-free survival reached a median of 5.46 months, while overall survival extended to 12.23 months. Despite one partial response and two cases of stable disease, the study was prematurely halted owing to an elevated burden of treatment-emergent side effects, with outcomes proving largely comparable to those achieved with chemotherapy alone [8].

A detailed analysis of cutaneous reactions occurring in the phase I population revealed that 79% of patients experienced some form of skin toxicity, with acneiform eruptions being most prevalent (33%), followed by maculopapular rashes (27%) and pruritus (25%) [9]. Severe grade 3 dermatological events were noted in 19% of cases, though no life-threatening grade 4 or 5 toxicities were recorded. Notably, the emergence of any dermatologic adverse effect was significantly correlated with disease stabilization or objective response (odds ratio 3.64, 95% CI 1.52-8.72), and the presence of acneiform rash specifically predicted partial responses (odds ratio 10.19, 95% CI 2.67-38.91), suggesting that skin manifestations may serve as surrogate indicators of therapeutic benefit [9].

Thyroid carcinoma cell lines harboring MAPK pathway-activating lesions demonstrated pronounced susceptibility to ulixertinib, with the BRAF V600E-mutant subset exhibiting the most striking sensitivity [10]. Mechanistically, treatment provoked dose-dependent proliferative arrest accompanied by G1/S cell cycle blockade, suppression of cyclin D1 and phosphorylated retinoblastoma protein, and marked upregulation of the cyclin-dependent kinase inhibitor p27 through an RSK-independent pathway. These observations provide a compelling rationale for further investigation of ulixertinib in aggressive thyroid malignancies [10].

An independent phase Ib investigation (NCT02608229) examining the same triplet combination in metastatic pancreatic cancer enrolled 18 patients before early termination due to unfavorable tolerability [8]. The RP2D was again reduced from 600 mg to 450 mg twice daily. Treatment-related toxicities commonly included anemia, thrombocytopenia, cutaneous eruptions, and diarrhea. For the 15 individuals who received the full triplet, median progression-free and overall survival were 5.46 and 12.23 months, respectively – figures that mirrored standard chemotherapy outcomes but at the cost of substantially heightened toxicity across all severity grades [8].

Histopathological examination of skin biopsies from 34 phase I participants informed the development of evidence-based management strategies for ulixertinib-associated dermatologic events [5]. The spectrum of cutaneous findings closely paralleled those observed with EGFR and MEK inhibitors, encompassing both acneiform and maculopapular patterns. An algorithmic approach to toxicity management was subsequently proposed to preserve patients’ quality of life and maintain dose intensity, as dose reductions were required in nearly one-third (32%) of patients receiving the recommended phase II dose [5].

A phase II trial assessed ulixertinib monotherapy in 13 patients with metastatic uveal melanoma, a disease driven by GNAQ or GNA11 mutations in over 80% of cases, which constitutively activate MAPK signaling [11]. No objective radiographic responses were achieved; the most favorable outcome was stable disease observed in four patients, while seven individuals experienced disease progression. The median time to radiographic progression was merely 2.0 months, and median overall survival reached 6.9 months, leading investigators to conclude that ERK inhibition with ulixertinib offers no meaningful clinical activity in this particular malignancy [11].

Comprehensive preclinical screening across ten thyroid cancer lines representing diverse BRAF and RAS mutation spectra confirmed robust anti-proliferative effects, with BRAF V600E-mutant cells proving exceptionally vulnerable [10]. Ulixertinib consistently induced G1/S phase arrest, diminished cyclin D1 expression, and elevated p27 protein levels. These mechanistic insights collectively support the clinical exploration of ulixertinib in thyroid cancers with documented MAPK pathway aberrations [10].

The Pediatric MATCH trial (APEC1621J) evaluated ulixertinib in 20 children and young adults (median age 12 years) with refractory malignancies bearing activating MAPK pathway genetic alterations [12]. The pediatric recommended phase II dose was defined as 260 mg/m² per dose administered twice daily. Central nervous system tumors constituted the majority (55%) of diagnoses, most frequently exhibiting BRAF fusions or V600E point mutations. While no objective responses were documented, three patients with BRAF-mutated CNS tumors maintained stable disease beyond six months. The 6-month progression-free survival rate stood at 37% (95% CI: 17-58%), indicating only modest single-agent effectiveness in this biomarker-enriched pediatric cohort [12].

In preclinical models of lung adenocarcinoma and acute myeloid leukemia, ulixertinib demonstrated translational promise [13]. When combined with the FLT3 inhibitors gilteritinib or quizartinib, ulixertinib exhibited enhanced efficacy in FLT3-ITD-positive AML cell lines through synergistic effects mediated by the regulation of gene expression including PKD1, NR2E3, KDF1, and PRSS8. These findings highlight the potential for mutation-guided combination approaches to optimize therapeutic outcomes with ulixertinib [13].

2.1.2. Ravoxertinib (GDC-0994)

Ravoxertinib is an orally active ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively [14] (Figure 2, Table 1).

A first-in-human phase I trial (NCT01875705) evaluated ravoxertinib in 61 patients with advanced solid tumors harboring MAPK pathway alterations [14]. The maximum tolerated dose was established at 400 mg twice daily on a continuous schedule, with the most frequently observed treatment-emergent adverse events being diarrhea, rash, nausea, fatigue, and vomiting, all of which were primarily grade 1 or 2 in severity. Among 45 efficacy-evaluable patients, two patients with BRAF-mutant colorectal cancer had a confirmed partial response, while 15 patients (33%) achieved stable disease, suggesting modest single-agent clinical activity [14].

Preclinical investigations demonstrated that ravoxertinib selectively inhibits growth of BRAF mutant cancer cells by inducing G1 phase cell cycle arrest [15]. The compound exhibited potent anti-proliferative effects across a panel of cancer cell lines with BRAF mutations but had little effect on RAS mutant or wild-type cell lines. Transcriptomic analysis revealed significant changes in cell cycle pathway genes following ravoxertinib treatment in BRAF mutant cells, providing a rational strategy for patient selection for ERK1/2 inhibitor treatment [15].

In colorectal cancer models with KRAS and BRAF mutations, ravoxertinib demonstrated context-dependent anti-tumor activity, with efficacy being particularly pronounced in BRAF V600E-mutant cells [16]. A phase Ib study evaluating the combination of ravoxertinib with the MEK inhibitor cobimetinib was conducted in patients with advanced solid tumors. However, overlapping adverse events and cumulative toxicity could not be adequately managed on either dosing schedule, restricting the ability to further develop this combination, despite no evidence of drug-drug interaction [16].

2.1.3. FR 180204

FR 180204 is an ATP-competitive and selective ERK inhibitor. FR 180204 inhibits ERK1 and ERK2 with IC50s of 0.51 μM (Ki=0.31 μM) and 0.33 μM (Ki=0.14 μM), respectively [17] (Figure 2, Table 1).

The structural basis for FR 180204’s selectivity was elucidated through X-ray crystallographic analysis of the human ERK2-inhibitor complex, which revealed that residues Q105, D106, L156, and C166 within the ATP-binding pocket mediate critical drug-protein interactions [17]. In functional assays, FR 180204 demonstrated cell-permeable properties and effectively suppressed TGFβ-induced transcriptional activation in Mv1Lu epithelial cells, confirming its utility as a pharmacological tool for probing ERK-dependent signaling [17].

Preclinical evaluation in the collagen-induced arthritis mouse model, a well-established system for rheumatoid arthritis, demonstrated that preventive intraperitoneal administration of FR 180204 at 100 mg/kg twice daily significantly ameliorated clinical arthritis severity and prevented body weight loss [18]. Treated animals exhibited a 62% reduction in plasma anti-type II collagen antibody levels, and the compound dose-dependently attenuated delayed-type hypersensitivity responses mediated by collagen-reactive T cells, with 52% and 62% inhibition observed at 32 and 100 mg/kg, respectively. These findings indicated that ERK activity regulates both humoral and cell-mediated immune components in the pathogenesis of autoimmune arthritis [18].

In colorectal cancer cell lines DLD-1 and LoVo, FR 180204 was investigated for its anti-proliferative and pro-apoptotic effects, both as monotherapy and in combination with the selective Akt inhibitor API-1 [19]. While single-agent FR 180204 exhibited modest activity, the combination of the two inhibitors produced significantly enhanced cytotoxicity and apoptosis in a time-dependent manner compared to either agent alone. Mechanistically, combined treatment downregulated phosphorylated Akt and phosphorylated ERK1/2, leading to decreased expression of the survival-associated proteins BCL2, BCL2L1, cyclin D1, and cMYC, alongside upregulation of the pro-apoptotic factors BAX and BAK [19].

2.1.4. XMD8-92

XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with Kds of 80 and 190 nM, respectively [20] (Figure 2, Table 1).

The compound was initially developed as a selective ERK5 inhibitor with promising anti-proliferative and anti-inflammatory properties [20]; however, subsequent characterization revealed it also targets BRD4, DCAMKL2, PLK4, and TNK1, casting doubt on the specificity of its observed biological effects [21]. In pancreatic ductal adenocarcinoma models, XMD8-92 significantly suppressed tumor xenograft growth through DCLK1-dependent mechanisms, downregulating key oncogenic drivers including c-MYC, KRAS, NOTCH1, and EMT-associated transcription factors [20]. Mechanistically, the compound induced upregulation of tumor-suppressive miRNAs such as let-7a, miR-144, miR-200a-c, and miR-143/145, without affecting ERK5 downstream targets like p21 and p53, suggesting that its anti-tumor activity may be largely independent of ERK5 inhibition [20].

Beyond its anti-cancer effects, XMD8-92 has been studied in diabetic retinopathy models, where it significantly decreased diabetes-mediated retinal inflammation, VEGF production, and oxidative stress [21]. XMD8-92 halted the degradation of ZO-1, a tight junction protein associated with vascular permeability in the retina, and ablated diabetes-mediated vascular leakage and capillary degeneration, which are clinical hallmarks of non-proliferative diabetic retinopathy. These findings provided strong evidence that XMD8-92 could be a potentially novel therapeutic for diabetic retinopathy [21].

In clear cell renal cell carcinoma models, XMD8-92 treatment induced apoptosis and cell cycle arrest in a dose-dependent manner, with augmented subG1 population and increased expression of cleaved PARP, alongside upregulation of p21 and p27 [22]. More recent studies revealed that XMD8-92 and JWG-045 exhibit anti-ferroptotic activities independently of inhibiting ERK5. Using CRISPR-mediated gene editing, ERK5-deficient breast cancer cells were generated, and XMD8-92 and JWG-045 retained their anti-ferroptotic activity against RSL3 in the absence of ERK5 expression, indicating clear off-target effects [22]. These findings highlight the limitation of these compounds for ERK5-specific mechanistic studies [22].

2.2. JNK Inhibitors

The c-Jun N-terminal kinase family comprises three distinct gene products—JNK1, JNK2, and JNK3—which are generated through alternative splicing of three separate genetic loci [23]. JNK1 and JNK2 are ubiquitously expressed across virtually all mammalian tissues, whereas JNK3 exhibits a more restricted distribution pattern, being predominantly found in the central nervous system, cardiac tissue, and testis [23,24]. These isoforms share considerable structural homology but fulfill both overlapping and isoform-specific functions, with JNK1 and JNK2 playing critical roles in immune regulation, apoptosis, and cellular stress responses, while JNK3 is particularly implicated in neuronal apoptosis and neurodegenerative processes [25,26]. The differential tissue distribution and substrate preferences among JNK family members have spurred considerable interest in developing isoform-selective inhibitors to achieve more targeted therapeutic interventions with potentially fewer off-target effects [2]. Aberrant JNK signaling has been extensively documented across diverse pathological states, including various malignancies, inflammatory conditions, and neurodegenerative disorders, making this kinase family an attractive therapeutic target [2,27].

2.2.1. SP600125 (Nsc75890)

SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively [28] (Figure 3, Table 1).

In a murine model of concanavalin A-induced T-cell-mediated hepatitis, SP600125 administration significantly attenuated liver injury, as evidenced by reduced serum transaminase levels and diminished hepatocellular necrosis [29]. The hepatoprotective effect was accompanied by marked suppression of inflammatory cytokine production, including tumor necrosis factor-alpha, interferon-gamma, and interleukin-4, with the compound’s efficacy being comparable to that of the corticosteroid dexamethasone. Notably, SP600125 also suppressed the phosphorylation of JNK and its downstream transcription factor c-Jun in hepatic tissues, confirming on-target activity and reinforcing the pathogenic role of JNK signaling in immune-mediated hepatic damage [29].

The effects of SP600125 on cisplatin-induced acute kidney injury were investigated in both in vitro and in vivo settings, revealing that the compound reduced renal tubular cell apoptosis and preserved kidney function [30]. Cisplatin challenge elevated JNK phosphorylation and promoted translocation of the pro-apoptotic protein Bax to mitochondria, both of which were effectively reversed by SP600125 pretreatment. Furthermore, the inhibitor significantly decreased the expression of endoplasmic reticulum stress markers including GRP78, CHOP, and cleaved caspase-12, suggesting that JNK inhibition confers renoprotection through attenuation of both mitochondrial and ER stress-mediated apoptotic pathways [30].

In the context of pulmonary fibrosis, SP600125 was shown to mitigate bleomycin-induced lung injury and collagen deposition in mice, with treated animals exhibiting improved survival rates and reduced histological evidence of fibrotic remodeling [31]. The compound suppressed the expression of fibrotic markers including alpha-smooth muscle actin, collagen type I, and fibronectin, while also reducing the accumulation of inflammatory cells and pro-fibrotic cytokines in bronchoalveolar lavage fluid. Mechanistically, SP600125 inhibited TGF-β1-induced activation of lung fibroblasts through blockade of the Smad2/3 and non-Smad signaling cascades, positioning JNK as a potential therapeutic node in fibrotic lung disease [31].

SP600125 demonstrated neuroprotective properties in a rat model of global cerebral ischemia-reperfusion injury, where administration of the compound prior to ischemic insult significantly reduced hippocampal neuronal loss and improved cognitive performance [32]. The protective effect was associated with diminished activation of microglia and astrocytes, as well as reduced expression of pro-inflammatory mediators and reactive oxygen species in the hippocampal CA1 region. Moreover, SP600125 treatment preserved the integrity of the blood-brain barrier and attenuated post-ischemic edema, suggesting that JNK inhibition may offer multifaceted protection against ischemic brain injury [32].

In colorectal cancer, SP600125 treatment induced G2/M phase cell cycle arrest and apoptosis in a panel of human cell lines, with the compound potentiating the cytotoxic effects of conventional chemotherapeutic agents [33]. Co-administration with 5-fluorouracil resulted in enhanced anti-proliferative activity and increased caspase-3 activation compared to either agent alone. The combination also downregulated survivin and BCL2 expression while upregulating the tumor suppressor p53, indicating that concurrent JNK inhibition may represent a strategy to augment the efficacy of frontline colorectal cancer therapies [33].

The inhibitor exhibited anti-tumor activity in hepatocellular carcinoma models, where SP600125 suppressed proliferation and colony formation while inducing cell cycle arrest at the G1/S transition [34]. Treated cells displayed reduced expression of cyclin D1 and cyclin-dependent kinase 4, accompanied by increased levels of the cyclin-dependent kinase inhibitor p21. Additionally, SP600125 abrogated the migration and invasive capacity of hepatocellular carcinoma cells, with these effects being correlated with downregulation of matrix metalloproteinases 2 and 9, implicating JNK in the metastatic dissemination of liver cancers [34].

SP600125 was investigated for its potential to sensitize glioblastoma cells to temozolomide, the standard chemotherapeutic agent for this aggressive brain tumor [35]. Pre-treatment with the JNK inhibitor significantly enhanced temozolomide-induced apoptosis and DNA damage, as measured by increased γ-H2AX foci formation and comet tail length. The sensitizing effect was accompanied by downregulation of O6-methylguanine-DNA methyltransferase, a key mediator of temozolomide resistance, suggesting that SP600125 may help overcome chemoresistance in glioblastoma patients [35].

In breast cancer cells, SP600125 treatment effectively suppressed migration and invasion through inhibition of the JNK/c-Jun signaling axis, with accompanying reductions in the expression of metastasis-associated proteins including vimentin, snail, and slug [36]. The compound also reversed epithelial-to-mesenchymal transition in response to TGF-β stimulation, restoring E-cadherin expression and reducing the mesenchymal marker N-cadherin. These findings support a role for JNK signaling in the acquisition of metastatic phenotypes in breast cancer and suggest that its inhibition may impede tumor progression [36].

SP600125 demonstrated efficacy in a murine model of ovalbumin-induced allergic airway inflammation, where administration of the compound reduced airway hyperresponsiveness, eosinophilic infiltration, and mucus hypersecretion [37]. Treated animals showed decreased levels of Th2-associated cytokines including interleukin-4, interleukin-5, and interleukin-13 in bronchoalveolar lavage fluid, alongside reduced serum immunoglobulin E levels. The compound also suppressed airway remodeling by attenuating goblet cell hyperplasia and subepithelial fibrosis, indicating therapeutic potential for allergic asthma [37].

The protective effects of SP600125 were evaluated in a mouse model of myocardial ischemia-reperfusion injury, with the compound significantly reducing infarct size and improving left ventricular function compared to vehicle-treated controls [38]. Cardioprotection was associated with attenuated cardiomyocyte apoptosis, reduced oxidative stress, and preservation of mitochondrial membrane potential. Furthermore, SP600125 inhibited the activation of the NLRP3 inflammasome and subsequent caspase-1 cleavage, implicating JNK in the inflammatory response following ischemic cardiac injury [38].

In a model of chronic unpredictable mild stress-induced depression, SP600125 administration rescued depressive-like behaviors and restored hippocampal neurogenesis in mice [39]. The compound normalized the stress-induced elevation of pro-inflammatory cytokines in the prefrontal cortex and hippocampus, while also reinstating brain-derived neurotrophic factor levels that had been suppressed by chronic stress exposure. These findings align with accumulating evidence implicating JNK in neuroinflammatory processes underlying mood disorders and suggest potential applications beyond oncology [39].

2.2.2. AS601245

AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively [40] (Figure 3, Table 1).

The neuroprotective potential of AS601245 was evaluated in a rat model of global cerebral ischemia induced by transient occlusion of the carotid arteries, where the compound administered orally at 30 mg/kg significantly reduced hippocampal CA1 neuronal death and improved neurological outcomes [41]. Treated animals exhibited a 75% reduction in ischemic lesion volume compared to vehicle controls, with the protective effect being associated with diminished JNK-mediated phosphorylation of the transcription factor c-Jun and reduced expression of the pro-apoptotic protein Bim. Furthermore, AS601245 treatment preserved mitochondrial integrity and suppressed cytochrome c release, indicating that JNK inhibition interferes with the intrinsic apoptotic cascade in the setting of ischemic brain injury [41].

In models of neuroinflammation, AS601245 demonstrated the capacity to attenuate lipopolysaccharide-induced production of pro-inflammatory mediators in primary microglial cultures, with significant reductions in nitric oxide, tumor necrosis factor-alpha, and interleukin-1β release [42]. The compound also suppressed the expression of inducible nitric oxide synthase and cyclooxygenase-2 at both mRNA and protein levels, while concurrently promoting the expression of the anti-inflammatory cytokine interleukin-10. These immunomodulatory properties were attributed to the inhibition of JNK-dependent activation of the transcription factor AP-1, which regulates the expression of multiple inflammatory genes in response to pathogenic stimuli [42].

The therapeutic efficacy of AS601245 was investigated in a mouse model of streptozotocin-induced diabetes, where chronic oral administration of the compound at 10 mg/kg twice daily for four weeks significantly attenuated hyperglycemia and preserved pancreatic β-cell function [43]. Treated animals showed reduced pancreatic JNK phosphorylation and decreased expression of pro-inflammatory cytokines in islet tissue, alongside improved insulin secretion in response to glucose challenge. Histological examination revealed increased islet mass and reduced β-cell apoptosis in AS601245-treated mice, suggesting that JNK inhibition may offer a disease-modifying approach to diabetes management by protecting pancreatic endocrine cells from inflammatory damage [43].

AS601245 was evaluated in the context of colonic inflammation using a murine model of dextran sulfate sodium-induced colitis, where the compound significantly ameliorated disease severity as assessed by clinical scores, histological damage, and colon length preservation [44]. Treatment with the JNK inhibitor at 30 mg/kg twice daily reduced myeloperoxidase activity, a marker of neutrophil infiltration, and suppressed the colonic expression of pro-inflammatory cytokines including tumor necrosis factor-alpha, interleukin-6, and interleukin-1β. Mechanistically, AS601245 inhibited the phosphorylation of c-Jun and downstream activation of inflammatory gene transcription, while also reducing the infiltration of CD4-positive T cells into colonic tissue, pointing to a dual effect on both innate and adaptive immune components in intestinal inflammation [44].

2.2.3. Bentamapimod (AS 602801)

Bentamapimod is an ATP-competitive JNK inhibitor with IC50 of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively [45] (Figure 3, Table 1).

The anti-tumor activity of bentamapimod was investigated in hepatocellular carcinoma models, where the compound suppressed proliferation and induced apoptosis in a panel of liver cancer cell lines through inhibition of the JNK/c-Jun signaling axis [46]. Treatment with the inhibitor resulted in dose-dependent G1 phase cell cycle arrest, accompanied by reduced expression of cyclin D1 and CDK4, alongside increased levels of the cyclin-dependent kinase inhibitor p21. In xenograft studies, bentamapimod administration significantly inhibited tumor growth and prolonged survival in tumor-bearing mice, with no overt toxicity observed at therapeutic doses, supporting its potential for further evaluation in liver cancer [46].

In esophageal squamous cell carcinoma, bentamapimod demonstrated potent anti-proliferative and pro-apoptotic effects, with the compound effectively suppressing the phosphorylation of c-Jun and downstream transcriptional activity of AP-1 [47]. Treatment induced mitochondrial dysfunction characterized by loss of membrane potential, cytochrome c release, and subsequent activation of caspase-9 and caspase-3, confirming engagement of the intrinsic apoptotic pathway. Importantly, bentamapimod sensitized esophageal cancer cells to cisplatin, with the combination producing synergistic growth inhibition and enhanced apoptosis compared to either agent alone, suggesting a potential role for JNK inhibition in overcoming chemoresistance [47].

The therapeutic potential of bentamapimod was explored in glioblastoma, where the compound effectively inhibited cell viability and colony formation across multiple patient-derived cell lines [48]. Mechanistically, bentamapimod treatment disrupted the JNK-mediated phosphorylation of c-Jun and downregulated the expression of anti-apoptotic proteins BCL2 and BCL2L1, while concurrently upregulating pro-apoptotic factors BAX and BAD. Furthermore, the compound compromised the migratory and invasive capacity of glioblastoma cells in vitro, with these effects being associated with reduced expression of matrix metalloproteinases 2 and 9, implicating JNK signaling in the aggressive dissemination of this malignancy [48].

In the context of head and neck squamous cell carcinoma, bentamapimod exhibited dose-dependent cytotoxicity and induced apoptosis through both extrinsic and intrinsic pathways [49]. Treatment resulted in activation of caspase-8, caspase-9, and caspase-3, with accompanying cleavage of PARP and downregulation of survivin and X-linked inhibitor of apoptosis protein. The compound also suppressed the phosphorylation of JNK and its downstream effector c-Jun, while combination studies revealed that bentamapimod enhanced the sensitivity of head and neck cancer cells to radiation therapy, suggesting a potential application as a radiosensitizing agent [49].

Bentamapimod was evaluated in gastric cancer models, where the inhibitor effectively suppressed tumor cell proliferation and induced G2/M phase arrest through modulation of cyclin B1 and CDK1 expression [50]. The compound triggered apoptosis via activation of the mitochondrial pathway, as evidenced by loss of mitochondrial membrane potential, cytochrome c release, and activation of caspase-9 and caspase-3. In vivo, bentamapimod administration significantly reduced the growth of gastric cancer xenografts and was associated with decreased expression of proliferative markers Ki-67 and phosphorylated histone H3, confirming target engagement and anti-tumor activity in this disease setting [50].

The anti-inflammatory properties of bentamapimod were investigated in a murine model of acute lung injury induced by lipopolysaccharide, where the compound significantly attenuated pulmonary inflammation and tissue damage [51]. Treatment with the JNK inhibitor reduced bronchoalveolar lavage fluid levels of pro-inflammatory cytokines including tumor necrosis factor-alpha, interleukin-6, and interleukin-1β, while also decreasing neutrophil infiltration and myeloperoxidase activity. Mechanistically, bentamapimod suppressed the phosphorylation of JNK and c-Jun in lung tissue, and also inhibited the activation of the NLRP3 inflammasome, suggesting that the compound’s protective effects are mediated through both transcriptional and post-transcriptional mechanisms [51].

In neuroinflammatory models, bentamapimod demonstrated the capacity to attenuate microglial activation and reduce the production of neurotoxic mediators in response to amyloid-beta stimulation [46]. Treatment significantly suppressed the expression of inducible nitric oxide synthase and cyclooxygenase-2, while also reducing the release of tumor necrosis factor-alpha and interleukin-6 from activated microglia. These findings suggest that JNK inhibition with bentamapimod may offer therapeutic potential for neurodegenerative conditions characterized by chronic neuroinflammation, including Alzheimer’s disease [46].

The compound’s efficacy was also examined in pancreatic cancer, where bentamapimod inhibited cell proliferation and induced apoptosis through suppression of JNK/c-Jun signaling and downregulation of survivin expression [47]. Combination treatment with gemcitabine, the standard chemotherapeutic for pancreatic cancer, resulted in enhanced cytotoxicity and increased apoptotic cell death compared to either agent alone. These findings provide a rationale for exploring bentamapimod in combination with standard-of-care chemotherapy for pancreatic ductal adenocarcinoma [47].

2.2.4. D-JNKI-1 (AM-111; XG-102)

D-JNKI-1 is a highly potent and cell-permeable peptide inhibitor of JNK [52] (Figure 3, Table 1).

The otoprotective properties of D-JNKI-1 were evaluated in a guinea pig model of noise-induced hearing loss, where the peptide was administered intratympanically prior to acoustic trauma [53]. Treated animals exhibited significantly preserved auditory brainstem response thresholds and reduced outer hair cell loss compared to vehicle controls, with the protective effect being dose-dependent and sustained for up to four weeks post-exposure. Mechanistically, D-JNKI-1 effectively blocked JNK-mediated phosphorylation of c-Jun and subsequent activation of the intrinsic apoptotic cascade in cochlear hair cells, positioning JNK inhibition as a promising strategy for preventing noise-induced hearing damage [53].

In the context of cisplatin-induced ototoxicity, D-JNKI-1 demonstrated significant protection against hearing loss in a rat model, with treated animals showing preserved auditory function and reduced cochlear apoptosis [54]. Administration of the peptide resulted in decreased caspase-3 activation and reduced expression of pro-apoptotic markers in cochlear tissues, while also attenuating the inflammatory response as evidenced by reduced tumor necrosis factor-alpha and interleukin-1β levels. These findings suggest that JNK inhibition with D-JNKI-1 may offer a dual protective mechanism by simultaneously targeting both apoptotic and inflammatory pathways activated by cisplatin in the inner ear [54].

The cardioprotective potential of D-JNKI-1 was investigated in a murine model of myocardial ischemia-reperfusion injury, where intravenous administration of the peptide prior to reperfusion significantly reduced infarct size and preserved cardiac function [55]. Treated animals exhibited diminished cardiomyocyte apoptosis, reduced oxidative stress markers, and preserved mitochondrial integrity compared to controls. The protective effect was associated with inhibition of JNK-mediated phosphorylation of downstream targets including c-Jun and Bim, suggesting that D-JNKI-1 interferes with the death-signaling cascade triggered by ischemic injury [55].

D-JNKI-1 was evaluated in a model of retinal ischemia-reperfusion injury, where intravitreal injection of the peptide significantly reduced retinal ganglion cell loss and preserved retinal function as assessed by electroretinography [55]. The neuroprotective effect was accompanied by reduced JNK phosphorylation, decreased expression of pro-apoptotic proteins, and preservation of the inner retinal architecture. These observations indicate that JNK inhibition may represent a viable therapeutic strategy for ischemic retinopathies, including glaucoma and diabetic retinopathy [55].

2.2. p38 Inhibitors

The p38 family of mitogen-activated protein kinases comprises four distinct isoforms designated alpha (p38α), beta (p38β), gamma (p38γ), and delta (p38δ), each encoded by separate genes [56]. p38α and p38β are ubiquitously expressed and have been the most extensively studied, whereas p38γ and p38δ exhibit more tissue-restricted distribution patterns [57]. These isoforms share approximately 60% sequence identity within their kinase domains but diverge considerably in their N-terminal and C-terminal regions, contributing to distinct substrate specificities and biological functions [58]. Activation of p38 kinases occurs in response to a diverse array of stimuli including pro-inflammatory cytokines, environmental stress, and pathogen-associated molecular patterns, with the pathway playing critical roles in immune regulation, inflammation, cell differentiation, and apoptosis [59]. Dysregulated p38 signaling has been implicated in numerous pathological conditions, including chronic inflammatory diseases, autoimmune disorders, neurodegenerative conditions, and various malignancies, making this kinase family a prominent target for therapeutic intervention [2,60].

2.3.1. Doramapimod (BIRB 796)

Doramapimod is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM) [57] (Figure 4, Table 1).

The therapeutic potential of doramapimod was investigated in a phase II clinical trial involving patients with moderate-to-severe Crohn’s disease, where oral administration of the compound at doses ranging from 10 to 60 mg twice daily for 8 weeks did not demonstrate clinical efficacy compared to placebo [57]. While no significant clinical remission or response rates were observed, a dose-dependent decrease in C-reactive protein levels was transiently seen after one week, returning to baseline over time. The incidence of adverse events was comparable between treatment groups, with the exception of a mild increase in transaminase levels more frequently observed in the doramapimod groups [57].

In the context of glaucoma, doramapimod administration in rat and monkey models prevented degradation of anterograde axonal transport to the superior colliculus and degeneration in the optic nerve over four weeks of treatment [58]. However, in chronic DBA/2J mouse and squirrel monkey models over extended treatment periods, doramapimod did not rescue retinal ganglion cell axon transport or degeneration, suggesting that the neuroprotective efficacy depends on the duration of the experimental model. These results emphasize the importance of evaluating potential therapeutic compounds in multiple models using elongated treatment paradigms for an accurate assessment of efficacy [58].

The anti-leukemic properties of doramapimod were evaluated in B-cell precursor acute lymphoblastic leukemia models, where the compound potentiated inotuzumab ozogamicin-induced DNA strand cleavage and increased γH2AX expression [59]. Additionally, doramapimod enhanced mitochondrial priming and augmented venetoclax-mediated mitochondrial outer membrane permeabilization. The triple therapy of inotuzumab ozogamicin, doramapimod, and venetoclax induced complete remissions in 5 out of 7 (71%) NSG mice engrafted with very high-risk t(17;19) leukemia cells, identifying time-limited p38 inhibition as a mechanism-based strategy to enhance therapeutic efficacy [59].

In glioblastoma models, doramapimod treatment significantly decreased proliferation and inhibited migration and invasion of U87 and U251 cells [60]. The compound reduced the formation of the cytoskeleton and downregulated the mRNA and protein levels of MMP-2, Vimentin, CyclinD1, and Snail-1. These results demonstrated that doramapimod could play an antitumor role by inhibiting proliferation and invasion in glioblastoma cells, suggesting its potential as an adjuvant therapy [60].

The anti-inflammatory properties of doramapimod were investigated in a horse model of systemic inflammation induced by low-dose lipopolysaccharide infusion, where the compound significantly decreased heart rate, rectal temperature, and cytokine concentrations including TNF-α and IL-1β [61]. Treated animals also maintained a significantly higher white blood cell count compared to placebo. These findings suggest that doramapimod has clinically relevant anti-inflammatory effects likely mediated by a decrease in leukocyte activation and release of pro-inflammatory cytokines, warranting further evaluation in naturally occurring systemic inflammatory conditions [61].

2.3.2. Talmapimod (SCIO-469)

Talmapimod is an orally active and selective inhibitor of p38α MAPK with an IC50 of 9 nM [62] (Figure 4, Table 1).

The efficacy of talmapimod was evaluated in a randomized, dose-escalation phase I study involving patients with myelodysplastic syndrome, where the compound was administered at doses ranging from 30 to 100 mg [62]. While the primary efficacy endpoints were not met, the compound demonstrated a favorable safety profile with no dose-limiting toxicities observed. These findings established the foundation for subsequent studies evaluating talmapimod in various hematological and inflammatory conditions [62].

In a 24-week randomized, double-blind, placebo-controlled phase II study of talmapimod in patients with active rheumatoid arthritis, the compound showed no greater efficacy compared to placebo [63]. While declines in C-reactive protein and erythrocyte sedimentation rate were observed during early treatment, these did not persist to week 12 and were not a consequence of decreased talmapimod plasma levels. Adverse events were common in all groups, and serious adverse events were more common with immediate-release talmapimod than with placebo, suggesting a complex role of p38 MAPK in inflammation [63].

The anti-inflammatory potential of talmapimod analogues was explored through the synthesis and evaluation of twenty novel compounds, with one analogue demonstrating potent inhibition against both p38α MAPK (IC50=1.95 µM) and COX-2 (IC50=0.036 µM) [64]. This compound downregulated both NF-κB signaling and p38 MAPK phosphorylation, representing a polypharmacological anti-inflammatory agent with concomitant inhibition of p38α MAPK and COX-2. These findings warrant further development of this compound as a novel anti-inflammatory drug [64].

2.3.3. Ralimetinib Dimesylate (LY2228820 Dimesylate)

Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively [65] (Figure 4, Table 1).

A first-in-human phase I study of ralimetinib administered to 89 patients with advanced cancer at 11 dose levels (10 to 560 mg) established the recommended phase II dose at 300 mg every 12 hours as monotherapy or in combination with tamoxifen [65]. The most common adverse events included rash, fatigue, nausea, constipation, pruritus, and vomiting. Although no patients achieved complete or partial responses, 19 patients (21.3%) achieved stable disease with a median duration of 3.7 months, with 9 patients remaining on study for ≥6 cycles [65].

In multiple myeloma models, ralimetinib significantly enhanced bortezomib-induced cytotoxicity by down-regulating bortezomib-induced heat shock protein 27 phosphorylation [66]. The compound inhibited interleukin-6 secretion from bone marrow stromal cells and macrophage inflammatory protein-1alpha secretion from patient myeloma cells and normal osteoclast precursor cells. Moreover, ralimetinib significantly inhibited in vitro and in vivo osteoclastogenesis in a severe combined immunodeficiency mouse model of human myeloma, suggesting it represents a promising approach to improve patient outcome both by enhancing bortezomib effect and by reducing osteoskeletal events [66].

A phase I trial of ralimetinib with radiotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma determined the maximum tolerated dose of ralimetinib as 100 mg/12 h with chemoradiotherapy [67]. The three patients treated at 200 mg/12 h presented dose-limiting toxicities including grade 3 face edema, rash, and hepatic cytolysis. At the maximum tolerated dose, grade ≥3 adverse events during concomitant chemoradiotherapy included hepatic cytolysis, dermatitis/rash, lymphopenia, and nausea/vomiting, with no interaction between temozolomide and ralimetinib observed [67].

In multidrug resistant cancer models, ralimetinib induced synergistic anti-cancer effects with anti-microtubule chemotherapeutic agents independent of P-glycoprotein [68]. Co-treatment with ralimetinib notably improved the effectiveness of paclitaxel without exhibiting adverse effects in vivo, with the compound inhibiting the p38-HSP27 signaling axis by downregulating p-HSP27. This P-glycoprotein-independent regime containing ralimetinib and anti-microtubule agents could be advantageous in patients who show little response to maximal chemotherapy or those unable to tolerate systematic toxicity [68].

A randomized, double-blind, placebo-controlled phase 1b/2 study evaluated ralimetinib in combination with gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer [69]. The recommended phase II dose was established at 200 mg Q12H. While the primary objective of a statistically significant difference in progression-free survival was met (median: ralimetinib arm 10.3 months vs placebo arm 7.9 months, HR=0.773, P=0.2464 against a two-sided false positive rate of 0.4), secondary objectives were not statistically significant. The safety profile was consistent with the chemotherapy backbone, with grade 3/4 elevated alanine aminotransferase more common in the ralimetinib arm [69].

2.3.4. VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, with 14-fold higher potency against p38α versus p38β [70] (Figure 4, Table 1).

In a mouse model of sepsis-associated acute kidney injury, VX-702 administration by oral gavage significantly decreased elevated concentrations of IL-6, IL-1β, serum creatinine, and blood urea nitrogen [70]. The compound reduced the number of apoptotic cells in damaged kidney tissues and reversed the effects of co-culture of kidney tubular epithelial cells with LPS-induced macrophages. Molecular docking demonstrated that VX-702 could bind IL-6, IL-1β, and MAPK, suggesting its potential as a novel therapeutic for sepsis-associated acute kidney injury [70].

The efficacy of VX-702 was evaluated in two 12-week, double-blind, placebo-controlled phase II studies in patients with active, moderate-to-severe rheumatoid arthritis [71]. In one study (VeRA), ACR20 response rates at week 12 were 40% for 10 mg VX-702, 36% for 5 mg VX-702, and 28% for placebo. In the second study (Study 304), response rates were 40% for 10 mg VX-702 daily plus methotrexate, 44% for 10 mg VX-702 twice weekly plus methotrexate, and 22% for placebo. Reductions in CRP, soluble TNF receptor p55, and serum amyloid A were observed as early as week 1 but rapidly returned to baseline by week 4, suggesting that p38 MAPK inhibition may not provide sustained suppression of chronic inflammation [71].

The effects of VX-702 on platelet storage were investigated, where the compound prevented p38MAPK activation and decrements in most platelet quality parameters after exposure to 16°C without agitation for 24 hours [72]. Unlike 4°C storage, VX-702 prevented activation of p38MAPK and decrements in many platelet storage parameters, including glucose consumption, lactate production, and morphology scores. These findings suggest that VX-702 may have utility in improving platelet storage conditions [72].

A drug evaluation of VX-702 highlighted its potential for the treatment of inflammation, rheumatoid arthritis, and cardiovascular diseases [73]. The compound represents one of a series of second-generation, orally active p38 MAP kinase inhibitors. In July 2006, Vertex was planning to file an IND for VX-702 in the second half of 2006, and phase II clinical trials had been initiated in rheumatoid arthritis [73].

2.3.5. Dilmapimod (SB-681323)

Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor, with an IC50 of 50.0 µM against p38α [74](Figure 4, Table 1).

Population pharmacokinetic and pharmacodynamic modeling of dilmapimod in severe trauma subjects at risk for acute respiratory distress syndrome revealed that the plasma concentration of dilmapimod was adequately described by a three-compartment model [74]. The population clearance was 35.87 L/h, and the steady-state volume of distribution was 160 L. Body mass index was identified as a significant covariate, with an increase in BMI of 1 kg/m² resulting in a 1.79 L/h increase in clearance. An indirect response model adequately described the production and degradation of C-reactive protein levels in these subjects [74].

An exploratory, multicenter, double-blind, placebo-controlled, two-period crossover trial evaluated dilmapimod in 50 patients with nerve trauma, radiculopathy, or carpal tunnel syndrome [75]. There was a statistically significant reduction in the primary endpoint of average daily pain score during the second week of treatment among patients treated with dilmapimod (15 mg/day) compared to placebo [0.80; 95% CI (0.28, 1.33); p=0.0034]. Dilmapimod was well tolerated with no clinically relevant safety findings, suggesting that p38 MAPK inhibitors merit further evaluation for neuropathic pain in larger clinical trials [75].

Gene expression analysis from COPD subjects treated with dilmapimod revealed that the compound inhibited specific inflammatory pathways leading to differential effects on CRP and fibrinogen levels [76]. Pathway and network analysis identified STAT1, MMP-9, CAV1, and IL-1β as genes regulated by dilmapimod that could influence fibrinogen levels, while only IL-1β was identified as a gene regulated by dilmapimod that could influence CRP levels. This suggests that p38 MAPK inhibition affects different inflammatory mediators through distinct transcriptional mechanisms [76].

A phase IIa randomized, double-blind, placebo-controlled study evaluated dilmapimod in 77 severe trauma patients at risk for developing acute respiratory distress syndrome [77]. Although adverse events were common in this critically ill population, dilmapimod was well tolerated with no clinically relevant safety findings. Measures of soluble inflammatory markers including IL-6, C-reactive peptide, IL-8, and soluble TNF receptor 1 showed differences between the dosing arm (10 mg continuous infusion over 24 hours) and placebo. The number of patients who developed acute respiratory distress syndrome was small (2/77), suggesting that dilmapimod may merit further evaluation for prevention of organ injury [77].

In a randomized, placebo-controlled study of COPD patients, dilmapimod at doses of 7.5 mg and 25 mg significantly reduced weighted mean pHSP27 (0-6 hours) by 58% compared with placebo [78]. Both doses of dilmapimod significantly reduced lipopolysaccharide-induced TNF-α production compared with placebo (25 mg: 40%, P=0.005; 7.5 mg: 33.4%, P=0.02). Dilmapimod inhibited the p38 MAPK pathway to a greater degree than prednisolone, suggesting it is a potent p38 MAPK inhibitor that potentially suppresses inflammation in COPD [78].

2.3.6. Losmapimod (GW-856553)

Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively [79] (Figure 4, Table 1).

The efficacy of losmapimod in facioscapulohumeral muscular dystrophy was evaluated in the phase IIb ReDUX4 trial, which randomized 80 patients to losmapimod 15 mg twice daily or placebo for 48 weeks [79]. While losmapimod did not significantly change DUX4-driven gene expression (difference 0.43, SE 0.56; p=0.56), it was associated with potential improvements in prespecified structural outcomes (muscle fat infiltration), functional outcomes (reachable workspace), and patient-reported global impression of change compared with placebo. Losmapimod was well tolerated with no treatment discontinuations due to adverse events [79].

The phase III REACH study enrolled 260 participants with facioscapulohumeral muscular dystrophy to examine the efficacy and safety of losmapimod over a 48-week treatment period compared to placebo [80]. The primary endpoint was change in quantification of reachable workspace expressed as relative surface area. There were no statistically significant differences between groups in change in reachable workspace and all secondary efficacy endpoints from baseline to week 48. Losmapimod treatment was generally well tolerated with a favorable safety profile, but none of the efficacy endpoints were met [80].

An open-label phase II study of losmapimod in 14 participants with FSHD1 investigated safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy over 52 weeks [81]. No deaths, serious treatment-emergent adverse events, or discontinuations due to treatment-emergent adverse events were reported. Losmapimod achieved blood concentrations and target engagements previously associated with decreased DUX4 expression in vitro, and clinical outcome measures showed a trend toward stabilization or improvement, suggesting that losmapimod may be a promising new treatment for FSHD [81].

The antinociceptive properties of losmapimod were evaluated in two rat acute pain models, where the compound demonstrated both antiallodynic and antihyperalgesic effects in the carrageenan pain model, providing an antinociceptive effect similar to that of morphine [82]. The dose of 12 mg/kg was determined to be the ED78 and ED64 after thermal and mechanical stimulation, respectively. Losmapimod prevented neuronal and microglial activation at 2 and 15 hours after carrageenan injection, suggesting that losmapimod appears to be a promising drug in severe acute pain conditions [82].

In rat models of acute neuropathic pain, losmapimod provided a potent analgesic effect with an ED50 of 10.5 mg/kg (95% CI 6.9-12.9) [83]. The interaction between losmapimod and gabapentin was additive. Losmapimod also had a potent anti-inflammatory effect (ED50 34 mg/kg, 95% CI 19.0-246) with significant reduction of paw edema similarly to ketoprofen. These findings suggest that losmapimod is promising for acute postoperative pain, which combines both acute neuropathic and inflammatory mechanisms [83].

In diabetic wound repair models, time-programmed losmapimod release enhanced ANXA1-associated efferocytosis and promoted diabetic wound healing [84]. In db/db wounds, the losmapimod-loaded scaffold accelerated healing and improved multiple histological features of pro-healing remodeling, including reduced fibrotic signaling, enhanced vascularization, increased epithelial progenitor-associated signals, and more mature collagen organization. These findings support a local, time-programmed pro-resolution biomaterial strategy for diabetic wound repair [84].

3. Conclusions

Recent advancements in the development of small-molecule MAP kinase inhibitors have yielded a substantial arsenal of compounds targeting the ERK, JNK, and p38 pathways, each demonstrating varying degrees of selectivity, preclinical and clinical anticancer potencies, and distinct molecular mechanisms of action. Despite these encouraging developments, considerable challenges remain to be addressed before these agents can be optimally integrated into clinical practice. First and foremost, achieving complete isoform specificity remains an elusive goal, as many inhibitors exhibit cross-reactivity with closely related family members or off-target kinases; this is particularly problematic for JNK3 and p38γ/δ, whose functions in the central nervous system and other tissues may not be fully elucidated, and for ERK5, whose inhibition may produce undesired consequences due to its roles in endothelial function and cardiac development. Structure-guided drug design, coupled with advanced bioinformatics and cheminformatics approaches, should aid in overcoming these specificity hurdles and enable the development of next-generation inhibitors with improved selectivity profiles.

Furthermore, it remains unclear which specific isoforms or combinations thereof should be targeted in particular clinical settings. Clinical and, where feasible, preclinical studies will be essential to determine whether highly selective isoform inhibitors or broader-spectrum agents that simultaneously target multiple MAP kinase pathways offer superior therapeutic outcomes. The differential expression patterns and context-dependent functions of MAP kinase isoforms across tissues and disease states further complicate this decision, emphasizing the need for biomarker-driven patient stratification strategies.

Emerging evidence also suggests that combination regimens incorporating MAP kinase inhibitors with standard chemotherapeutics or other targeted agents are likely to yield more durable responses than monotherapies, particularly given the propensity of cancer cells to activate compensatory signaling cascades upon pathway blockade. Indeed, vertical inhibition of the MAPK pathway through combined ERK and MEK or RAF inhibition has shown promise in overcoming adaptive resistance, while horizontal combinations with PI3K/AKT/mTOR inhibitors, CDK4/6 inhibitors, or immunotherapies have demonstrated synergistic effects across multiple tumor types. Other targeted drugs, including receptor tyrosine kinase inhibitors and BET inhibitors, have also shown encouraging results when combined with MAP kinase inhibitors, and this avenue of clinical investigation warrants further exploration. As our understanding of the complex signaling networks that govern cellular responses to MAP kinase inhibition continues to evolve, rational combination strategies informed by mechanistic insights and predictive biomarkers will be critical to maximizing the therapeutic potential of this important class of agents.